Drawing for LYNKEUS BIOTECH

USPTO serial 76412499

LYNKEUS BIOTECH

Reviewed by CopyMark Law Group

Reg. 2986751Status 710
Filing date
Status date
Registration date
Aug 23, 2005
Examiner
MCMORROW, JANICE LEE
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with LYNKEUS BIOTECH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

James D. DeCamp

JAMES D DECAMP CLARK & ELBING LLP101 FEDERAL STBOSTON, MA 02110UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemicals, namely, biochemical and molecular biological products for use in manufacture of pharmaceutical and veterinary pharmaceutical preparations for the diagnosis and therapy of degenerative diseases of the central nervous system, namely, diseases of the eye, diseases related to defects in vasculature or diseases related to vasculature and autoimmune diseases; chemicals, namely, biochemical products and molecular biological products in the nature of nucleic acid probes and antibodies for the detection of degenerative diseases of the central nervous system, the eye, vasculature, and for the detection of autoimmune diseases for scientific useSECTION 8 - CANCELLED—
005Pharmaceutical preparations for use in the treatment of degenerative diseases of the central nervous system, namely, diseases of the eye, diseases related to defects in vasculature or diseases related to vasculature and autoimmune diseases; veterinary pharmaceutical preparations for use in the treatment of degenerative diseases of the central nervous system, namely, diseases of the eye, diseases related to defects in vasculature or diseases related to vasculature and autoimmune diseases in domestic pets, live-stock, poultry, amphibians, teleosts and insects; preparations for healthcare, namely, dietetic products for medical purposes in the nature of dietary supplements, diet pills, dietary drink mix for use as a meal replacement, dietary food supplements, food for medically restricted diets, and meal replacement barsSECTION 8 - CANCELLED—
041Educational services, namely, conducting seminars, lectures, academies, colloquiums, conferences, congresses, symposiums, workshops, practical training, in the field of molecular biology, genetic engineering, and molecular diagnosticsSECTION 8 - CANCELLED—
042Scientific research; technical research in the field of chemistry, biology and diagnosis of neuronal, especially opthalmological indications like retinal degradations and of diseases related to defects in vasculature or diseases related to vasculature and of autoimmune diseases; scientific research in the field of gene therapy; laboratory research in the field of molecular biology, animal models and cell culture systems; chemist services, biochemist services; technical consultation and research in the fields of biology; mission oriented research and diagnostics, namely, diagnostic services in the field of diagnostic services in the field of diseases of the eye, diseases related to defects in vasculature, and autoimmune diseases and genetic, biochemical, and medical research; chemical and biochemical laboratories; genealogy research in the nature of generating of gene therapy-protocols; computer software development for data processing; consultation in the fields of molecular biology, genetic engineering, molecular diagnostics, gene therapy, and molecular medicine; research in the field of gene therapy and molecular medicineSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 21, 2012C8..CANCELLED SEC. 8 (6-YR)—
Aug 23, 2005R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 31, 2005PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 11, 2005NPUBNOTICE OF PUBLICATION—
Sep 9, 2004PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 26, 2004ALIEASSIGNED TO LIE—
Jun 29, 2004MAILPAPER RECEIVED—
Apr 29, 2004CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 4, 2004CFITCASE FILE IN TICRS—
Mar 3, 2004DOCKASSIGNED TO EXAMINER—
Dec 8, 20031.BDSec. 1(B) CLAIM DELETED—
Dec 8, 2003CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 8, 2003MAILPAPER RECEIVED—
Jun 5, 2003GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Mar 25, 2003CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 25, 2003MAILPAPER RECEIVED—
Oct 9, 2002DOCKASSIGNED TO EXAMINER—
Sep 23, 2002CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 9, 2002DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance